News & Analysis as of

France Reimbursements

Hogan Lovells

Market Access in Europe: Navigating Pricing & Reimbursement Pathways

Hogan Lovells on

In Europe, the regulation of pricing and reimbursement for medicinal products is primarily governed by national policies, as EU-level regulation is limited. Our latest brochure “Market Access in Europe: Navigating Pricing &...more

Hogan Lovells

The increasing legalisation of French market access positions is confirmed

Hogan Lovells on

The new amendments to the French framework agreement. The implementation of special hospital preparations and the amendment to the framework agreement concluded between the French professional organization of pharmaceutical...more

Hogan Lovells

Nouvelle doctrine de la Commission de la Transparence de la Haute Autorité de santé

Hogan Lovells on

Dans la continuité de son Plan d’action pour les médicaments innovants exposé début 2020, la Haute Autorité de santé a mis à jour sa doctrine d’évaluation des médicaments. ...more

White & Case LLP

Corona Pandemia & Partial Reduction of Activity in France

White & Case LLP on

Partial Reduction of Activity (“Activité partielle”) - All companies whose activity is reduced due to the COVID-19 and in particular, those that are subject to an obligation to close down in application of the Decree of 14...more

4 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide